Response to a letter from Meng Sun and Zhiqiang Zhao commenting on the article entitled “Antithrombotic approach in percutaneous pulmonary valve implantation (PPVI): What is our standard of care? A study endorsed by the Association for European Paediatric and Congenital Cardiology” - 11/03/26

Alessia Callegari ^{a, g, ⁎} , Gianfranco Butera ^b, Thomas Krasemann ^c, Ruth Heying ^d, Ina Michel-Behnke ^e, Damien Bonnet ^{a, f}, Sophie Malekzadeh-Milani ^a

^a Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Hôpital Universitaire Necker-Enfants Malades, AP–HP, 75015 Paris, France 

^b Cardiology, Cardiac Surgery and Heart Lung Transplantation, ERN GUARD HEART, Bambino Gesù Hospital and Research Institute, IRCCS, 00165 Rome, Italy 

^c Department of Paediatric Cardiology, Sophia Children's Hospital, 3015 GD Rotterdam, Netherlands 

^d Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven; and Department of Paediatric Cardiology, University Hospitals Leuven, 3000 Leuven, Belgium 

^e Division of Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine, Paediatric Heart Centre Vienna, Medical University of Vienna, 1090 Vienna, Austria 

^f Université de Paris Cité, 75006 Paris, France 

^g University Children's Hospital of Zurich, 8032 Zurich, Switzerland 

^⁎ Corresponding author. Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Hôpital Universitaire Necker-Enfants Malades, AP–HP, Rue de Sèvres, 75015 Paris, France. Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Hôpital Universitaire Necker-Enfants Malades, AP–HP Rue de Sèvres Paris 75015 France

Le texte complet de cet article est disponible en PDF.